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Abstract
Background: Accelerated treatment strategy, including tight disease control and early aggressive therapy with
immunosuppressives (IS) and biological agents have become increasingly common in inflammatory bowel disease
(IBD). The aim of the present study was to estimate the early treatment strategy and outcomes in newly diagnosed
patients with Crohn’s disease (CD) between 2004 and 2008 and 2009–2015 in the whole IBD population in Hungary
based on the administrative database of the National Health Insurance Fund (OEP).
Methods: We used the administrative database of the OEP, the only nationwide state-owned health insurance
provider in Hungary. Patients were identified through previously reported algorithms using the ICD-10 codes for
CD in the out-, inpatient (medical, surgical) non-primary care records and drug prescription databases between
2004 and 2015. Patients were stratified according to the year of diagnosis and maximum treatment steps during
the first 3 years after diagnosis.
Results: A total of 6173 (male/female: 46.12%/53.87%) newly diagnosed CD patients with physician-diagnosed
IBD were found in the period of 2004–2015. The use of 5-ASA and steroids remained common in the biological
era, while immunosuppressives and biologicals were started earlier and became more frequent among patients
diagnosed after 2009. The probability of biological therapy was 2.9%/6.4% and 8.4%/13.7% after 1 and 3 years in
patients diagnosed in 2004–2008/2009–2015. The probability of hospitalization in the first 3 years after diagnosis
was different before and after 2009, according to the maximal treatment step (overall 55.7%vs. 47.4% (p = 0.001),
anti-TNF: 73%vs. 66.7% (p = 0.103), IS: 64.6% vs. 56.1% (p = 0.001), steroid: 44.2%vs. 36.8% (p < 0.007), 5-ASA: 32.6%
vs. 26.7% p = 0.157)). In contrast, surgery rates were not significantly different in patients diagnosed before and
after 2009 according to the maximum treatment step (overall 16.0%vs.15.3%(p = 0.672) anti-TNF 26.7%vs.27.2%
(p = 0.993), IS: 24.1%vs22.2% (p = 0.565), steroid 8.1%vs.7.9% (p = 0.896), 5-ASA 10%vs. 11% (p = 0.816)).
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Conclusions: IS and biological exposure became more frequent, while hospitalization decreased and surgery
remained low but constant during the observation period.
Use of steroids and 5-ASA remained high after 2009. The association between the maximal treatment step and
hospitalization/surgery rates suggests that maximal treatment step can be regarded as proxy severity marker in
patients with IBD.
Keywords: Treatment strategy, Crohn’s disease, Inflammatory bowel disease, Biological therapy, Surgery,
Administrative database, Nationwide
Background
Inflammatory bowel diseases (IBD) are chronic conditions
affecting the patient’s quality of life, leading to disability;
moreover, a significant proportion of patients require sur-
gery. In the past decades, the prevalence of IBD increased
worldwide [1–3]. However, development of medical ther-
apy improved patients’ perspectives significantly. In recent
years, treatment strategies and therapeutic targets have
evolved: “treat-to-target” has become an important in-
patient management and therapeutic goals have been de-
termined [4]. Additionally, accelerated treatment strategy,
including tight disease control and early aggressive therapy
with immunosuppressives (IS) and biological agents
(mostly anti-TNFs) have become increasingly common in
IBD. Emerging data suggest that earlier introduction of IS
and biologicals may be associated with improved out-
comes including lower risk for surgery and hospitalization
[5–9]. These improvements in the management of IBD are
reflected by clinical guidelines as well [10]. Nevertheless, it
is important to investigate how these changing paradigms
affect every day clinical practice and clinical outcomes.
The recent ECCO-EpiCom studies based on the 2010
and 2011 inception cohorts provided data about up-to-
date IBD incidences, treatment steps and initial disease
course of IBD in the biological era in Europe. Differences
were reported between Western and Eastern Europe, not
only in the prevalence of IBD, but also regarding treatment
strategy and disease outcomes [11–13]. Data on the nat-
ural history and therapeutic strategies of Crohn’s disease
was also reported in population-based studies from
North-America, including data from the Mayo clinic,
Olmsted Country, Minnesota and the Manitoba Cohort,
Canada [8, 14, 15]. It is essential to note, that direct
comparison of the above studies may be difficult due to
differences in health care insurance systems and data
acquisition.
In Hungary, previous population-based studies on the
epidemiology and treatment strategy in IBD were re-
ported in the Veszprem population-based IBD database.
Nevertheless, data on medical strategy were reported
from the pre-biological era [16, 17]. Recently, our group
reported nationwide estimate of IBD prevalence from
the administrative database of the National Health
Insurance Fund [18]. However, the effect of medical
therapy on disease outcomes has not been studied yet.
Therefore, the aim of the present study was to investi-
gate the early treatment strategy and outcomes in newly
diagnosed patients with Crohn’s disease (CD) between
2004 and 2015 in Hungary. Since the prescription regu-
lations changed significantly at the end of 2008 with eas-
ier access to biologicals, it has been aimed to evaluate
surgical outcomes and hospitalization rates before and
after the change of prescription-regulations in the ad-
ministrative database of the National Health Insurance
Fund (OEP) which is the only (state-owned) health in-
surance provider in Hungary.
Methods
We used the administrative database of the National
Health Insurance Fund (OEP). Patients were identified
through previously reported algorithms using the ICD-
10 codes for Crohn’s disease (K50..) in the out- and in-
patient (medical, surgical) non-primary care records and
drug prescription databases between 1st of January 2004
and 1st of January 2015 [18]. Hospitalizations, surgical
episodes and drug prescriptions were identified through
the database of the OEP, which contains data on in- and
outpatient stays, outpatient procedures and filled drug
prescriptions. Any event with a CD-related ICD-10 code
was regarded as related.
New patients with Crohn’s disease was defined as no
CD-related outpatient visits and/or IBD-related drug pre-
scriptions in the last 3 years before the start of the obser-
vational period and at least 2 CD-related outpatient visits
and/or IBD-related drug prescription during the observa-
tional period. Patients with less than 3 years follow up
were excluded from the study. Patients were stratified ac-
cording to the year of diagnosis and the maximum treat-
ment step during the first 3 years after diagnosis.
We determined time to prescription of different drug
classes, (5-ASA, steroid, IS and biologicals) and stratified
patient groups according to the maximal therapeutic
step (1. group – maximum therapeutic step: 5-ASA ther-
apy (oral and/or topical 5-ASA treatment), 2. group –
maximum therapeutic step: steroid therapy (systemic or
topical steroids), 3. group – maximum therapeutic step:
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IS therapy (azathioprine, 6-mercaptopurine, cyclosporine
or methotrexate), 4. group – maximum biological ther-
apy (infliximab or adalimumab)). Finally, we calculated
hospitalization and surgery rates according to the max-
imal treatment step and the diagnostic period (diagnosis
in 2004–2008 vs. 2009–2015).
Statistical methods
SPSS® 20 (SPSS Inc., Chicago, IL) was used for statistical
analysis. Khi-square test and Fischer-exact tests were
used to compare categorical variables. Kaplan-Meier
analysis and Cox-Mantel LogRank test was used for time
dependent change of the categorical variables. Time
from diagnosis were weighted to 30-days periods in the
Kaplan-Meier analysis. A p value of < 0.05 was regarded
as statistically significant.
Results
Patient characteristics
A total of 6173 (male/female: 46.12%/53.87%) newly di-
agnosed CD patients with physician-diagnosed Crohn’s
disease were found between 2004 and 2015. 4458 and
1715 newly diagnosed CD patients with an available 3-
year follow up period were identified between 01.01.2004
and 31.21.2008 and between 01.01.2009 and 01.01.2015.
Distribution of age at diagnosis was similar in the two
diagnostic eras, the most prevalent age group at the diag-
nosis of Crohn’s disease was the 20–29 years old group in
both gender and in both diagnostic eras (Fig. 1).
Therapeutic strategy
Drug exposures were calculated in a time dependent
analysis. The cumulative probability of 5-ASA, steroid,
IS and biological therapy were 95.7, 74.8, 37.1 and 4%
after 12 months and 97.7, 81.3, 49.4 and 9.9% after
3 years from diagnosis (Fig. 2).
The use of 5-ASA was 93%/90.8% after 3 months and
97.9%/97.1% after 3 years from the diagnosis in the
whole patient groups diagnosed before and after 2009,
and it did not differ according to the different maximal
treatment steps. Use of 5-ASA was similar in the two
diagnostic eras in each patient group.
Cumulative steroid exposure was also comparable in
both groups (64.4%/66% after 3 months, 72.6%/74.2%
after 12 months, 79.8%/79.9% after 3 years in patients
diagnosed before and after 2009). Probability of early
steroid exposure was different according to the max-
imum treatment step but not according to the year of
Fig. 1 Age and gender distribution of newly Crohn’s disease patients diagnosed in 2004–2008/2009–2015
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diagnosis: it was 48.9%/53.5% after the first 3 months
from diagnosis in patients with steroids as maximum
treatment step (pLogRank = 0.09), 74%/74.8% in patients
with IS as maximum treatment step (pLogRank = 0.95)
and 81.2%/78.7% in patients with biological therapy as
maximum step (pLogRank = 0.31), in patients diagnosed
before and after 2009 (Fig. 3).
Exposure to immunosuppressive therapy was frequent
in both diagnostic eras, with higher probability
(pLogRank < 0.001 for the max. IS group and p = 0.007
for the max. Biological group) and earlier initiation in
the second period. Probability of immunosuppressive
therapy was 17.5% vs. 22.9% at 3 months, 29.3% vs. 35.4%
at 1 year and 39.9% vs. 45.2% at 3 years in 2004–2008 vs.
2009–2015 in patients with IS as maximum treatment
step. Exposure of IS was higher in patients needing
anti-TNF therapy: 31.5% vs. 40.3% at 3 months, 66.7%
vs. 73.1% at 1 year and 86.7% vs. 91.8% at 3 years in
2004–2008 vs. 2009–2015 (Fig. 4).
The probability of biological therapy was significantly
higher in patients diagnosed between 2009 and 2015
(pLogRank< 0.001). It was 1% vs. 1.2% after 3 months,
2.9% vs. 6.4% after 1 year and 8.4% vs. 13.7% after 3 years
in 2004–2008 vs. 2009–2015 (Fig. 5).
Fig. 2 The cumulative probability of 5-ASA, steroid, IS and biological therapy in the whole observation period
Fig. 3 Probability of steroid therapy according to the maximum treatment steps
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Hospitalizations and surgery rates according to the
maximal treatment steps in the biological era
Probability of hospitalizations in the first 3-years after
the diagnosis was significantly lower in patients
diagnosed in 2009–2015 than in patients diagnosed in
2004–2008 (total probability: 55.7% vs. 47.4% in patients
diagnosed in 2004–2008 vs. in 2009–2015, pLogRank
< 0.001 for the total cohort). When we analysed the
hospitalization rates according to the maximal treat-
ment steps, the difference was significant in the ster-
oid and IS group (total probabilities: 5-ASA group:
32.6% vs. 26.7% pLogRank = 0.16, Steroid group:
44.2% vs. 36.8% pLogRank = 0.007, IS group: 64.6% vs.
56.1% pLogRank< 0.001, Biological group: 73% vs.
66.7% pLogRank = 0.10) (Fig. 6).
In contrast, surgery rates were altogether low and not
significantly different in the two periods, but they were
associated with the maximum therapeutic step. A pro-
portion of patients underwent surgery at around the
time of diagnosis (within 3 months from diagnosis) in
both diagnostic eras, regardless of the maximum treat-
ment step (9.1%/8.6% in the total cohort in 2004–2008/
2009–2015). Thereafter the probability of surgery
remained unchanged in patients with 5-ASA and steroid
only, while it increased continuously in the IS and bio-
logical group (at 1 year: overall: 12% vs. 11.9%, biological
therapy: 20.9% vs. 19.6%, IS: 17.4% vs. 17.3%, steroid 5.8%
vs. 6%, 5-ASA 8.9% vs. 9.1%, at 3 years: overall: 16.0% vs.
15.3% (pLogRank = 0.672), biological therapy: 26,7% vs.
27.2% (pLogRank = 0.993), IS: 24.1% vs. 22.2% (pLogRank
= 0.565), steroid 8.1% vs. 7.9% (pLogRank = 0.896), 5-ASA
10% vs. 11% (pLogRank = 0.816) in patients diagnosed in
2004–2008 vs. 2009–2015) (Fig. 7).
Discussion
The aim of the present study was to demonstrate a na-
tionwide description about the therapeutic strategy and
outcomes in newly diagnosed patients with Crohn’s
disease in the biological era in Hungary.
The main findings of the study were that
hospitalization but not surgical rates differed signifi-
cantly in patients diagnosed between 2004 and 2008 and
between 2009 and 2015, along with the earlier and more
frequent use of IS and biologicals in the second diagnos-
tic period. Of note, surgery rates were altogether low. In
addition, hospitalizations and surgeries were more fre-
quent in the biological and the IS group compared to
patients with steroids and 5-ASA only, suggesting that
maximal therapeutic steps can be used as severity
markers in patients with IBD when analysing health in-
surance databases.
In the present study, the overall probability of surgery
was 9.1%/8.6% after 3 months, 12%/11.9% after 1 year
and 16%/15.3% after 3 years from diagnosis among pa-
tients diagnosed in 2004–2008/2009–2015. This is in
Fig. 4 Probability of immunosuppressive therapy according to the diagnostic period and the maximal treatment steps
Fig. 5 Probability of biological therapy according to the
diagnostic period
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line with new data reported after 2000 [6]. According to
the meta-analysis of Frolkis et al. based on 30
population-based studies, the cumulative risk of surgery
in CD-patients diagnosed in the 2000s was 12.6 and
24.2% after 1 and 5 years from diagnosis [19]. The study
from Manitoba also reported that probability of surgery
was 10% and 18% after 1 and 5 year from diagnosis in
CD patients diagnosed after 2000 [8]. In contrast,
ECCO-EpiCom 2011 inception cohort study showed that
24 and 7% of patients from Eastern Europe and Western
Europe/Australia underwent surgery within the first year
of diagnosis [13].
Interestingly, the present study demonstrated that a
stable proportion of patients (app. 9%) had surgery at
around the diagnosis (within 3 months from diagnosis)
in both diagnostic eras, independently from the
maximum treatment step and further disease course.
Similarly, Solberg et al. reported that very early CD-
related surgery rates remained unchanged and did not
influence long term clinical remission rates or outcomes
[20]. In contrast, a recent study from Portugal concluded
that patients undergoing an early surgery after diagnosis
have an increased reoperation rate [21]. Of note, the rate
of early surgery within 1 year from diagnosis remained
stable in most epidemiological cohorts suggesting that at
least a propostion of early surgeries can be regarded as
unavoidable [6, 19].
Furthermore, our results suggest that the earlier and
more frequent use of biological therapy did not reduce
the probability of early surgery during the first 3 years
from diagnosis. Previous population-based studies re-
ported that the need for surgery significantly decreased
between the 1980s and 2000s, parallel with the increased
use of immunosuppressives [7, 8, 22]. Similarly, a former
study from Hungary demonstrated that increased and
earlier azathioprine use was independently associated
with significant change in the natural history of CD and
reduced surgery rates [17]. However, only few
population-based studies are available from the bio-
logical era, and it is still conflictive whether biological
therapy further decreases surgical rates on a population-
based level [6, 23]. A recent meta-analysis based on 7
randomized controlled trial studies concluded that anti-
TNFs were efficacious in reducing hospitalization and
Fig. 6 Probability of hospitalization according to the maximum treatment steps in patients diagnosed in 2004–2008/2009–2015
Fig. 7 Probability of surgery according to the maximum treatment steps in patients diagnosed in 2004–2008/2009–2015
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surgery rates compared to placebo, while no statistically
significant reduction was noted to azathioprine (AZA)
and vedolizumab in moderate-to-severe CD patients
[23]. Similarly to our findings, a Spanish study con-
cluded that IFX availability did not reduce surgical
requirements with a step-up therapeutic algorithm in
newly diagnosed CD patients [24]. Moreover, a study
based on the Manitoba-cohort suggested that decline in
surgery was associated with the care by a gastroenter-
ology specialist but not with the immunomodulatory use
in multivariate analysis. This study also concluded that
use of more aggressive medical therapy can be a severity
marker in non-randomized trial settings [8]. Further-
more, the recent update of the 5-years follow-up of the
2010 ECCO-EpiCom inception cohort study also
reported that similar surgery and hospitalization rates
were shown in Eastern and Western Europe, despite of
more early and aggressive treatment with biologicals in
Western Europe [25]. A study from Northern California
concluded that prevalence of prolonged steroid exposure
and hospitalization rates declined, whereas surgery rates
remained constant in parallel with the increasing use of
IS and biologicals in CD [26].
The probability of hospitalization was frequent around
the diagnosis, but thereafter the frequency of
hospitalization was not associated with the maximal
therapeutic steps in the present study. Frequency of
hospitalization was lower in all treatment groups in the
second diagnostic period (decrease was significant in the
steroid and IS group), showing a change in the patient
management and the possible role of the accelerated
treatment strategy. These results are in concordance
with previous data that hospitalization is frequent
around the diagnosis but it declines significantly from
the second year after the diagnosis [27, 28]. Neverthe-
less, hospitalization rates vary significantly between
countries, depending on health care/reimbursement
policy and ethnic differences [2, 6].
The other primary aim of the study was to analyse the
therapeutic strategy in the two diagnostic eras. Surpris-
ingly, almost every CD patient received 5-ASA therapy
in Hungary at around the diagnosis. This result is in
concordance with the result of the ECCO-EpiCom 2011
inception cohort study and with other nationwide stud-
ies [13, 14]. Possible explanations are that physicians
prescribe 5-ASAs until the diagnosis is finally confirmed
or patients with mild CD are given 5-ASAs for mainten-
ance therapy. Similarly, a national survey from Germany
showed that app. 40% of physicians followed “wait and
see” management strategy without any medical therapy
in mild CD patients as maintenance, while third of
physicians preferred 5-ASA in these cases [29].
Interestingly, the use of steroids remained common in
both periods. The majority of patient received steroid
therapy as initial treatment at diagnosis and it increased
slightly over time. Compared to other recent
population-based studies, the use of steroids was more
frequent in the present cohort. In previous population-
based studies the half of the CD patients received ste-
roids during the early disease course [8, 30, 31]. Other
studies showed steroid sparing effect of the increased
IS and biological use [7, 26]. In contrast, the ECCO-
EpiCom 2011 inception cohort reported that 61 and
67% of patients from Eastern Europe and Western
Europe/Australia received systemic steroids during the
first year of disease course [13].
The use of immunosuppressives was more frequent in
the second period with earlier initiation. This suggests
an accelerated step-care strategy in Hungary, similarly to
those reported from the Spanish Administrative
Database [24]. In the first period, the probability of IS
use after 1 year from diagnosis was similar to the previ-
ous data from Hungary from the same decade (35.5% vs.
34.8%), while rate of IS use in the second period was
higher, similar to rates from Western-Europe (41.3% vs.
45%) [13, 16, 32].
Finally, the use of biologicals was more frequent with
earlier initiation in the second period in accordance with
the changes of the drug prescription guidelines of OEP
allowing an earlier and more extensive availability of
anti-TNFs after 2009 in Hungary. In a previous study by
Rencz et al. Hungary had the best access to biologicals
in IBD in Central-Eastern Europe [33]. However, the use
of biological therapy was in line with the Eastern
European data in the 2010 ECCO EpiCom inception
cohort study, it remained less frequent compared to
Western Europe [25, 32].
The authors are aware of the possible limitations of
the present work including the limitations of adminis-
trative databases such as the lack of disease phenotype
data, time bias due to patient stratification or possible
bias of patient ascertainment. In contrast, the strength
of the present study is the nationwide nature of the
study. The administrative database of the National
Health Fund is unique in many regards, as in Hungary
this is the only insurance plan with a full coverage and
it collects in-, outpatient visits, diagnostic procedures
and drug prescription data. Thus, it offers an invaluable
opportunity to study treatment practices and changes
in outcomes representative for the full spectrum of IBD
patients in Hungary. Moreover, earlier publications sug-
gested that the first 3-years of the disease are the most
sensitive and representative for the further disease
course [16, 34]. Thus, results from the present study
can be extrapolated in the prediction of the further dis-
ease course as well as may be generalizable to most ad-
ministrative databases from countries with similar
health insurance policies.
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Conclusion
In conclusion, the present study, representing the nation-
wide practices in Hungary suggests, that there is an accel-
erated therapeutic strategy in CD in Hungary with IS and
biological use becoming more frequent. Hospitalization
decreased in the whole cohort, while surgery remained
low but constant during the observation period.
Exposure to steroids and 5-ASA remained high. The
association between maximal treatment step and
hospitalization and surgery rates suggests that maximal
treatment steps can be regarded as proxy severity
markers in patients with IBD.
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